Free Trial

Aptevo Therapeutics (APVO) Competitors

-0.02 (-6.01%)
(As of 07/12/2024 ET)


Should you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include Hoth Therapeutics (HOTH), Mainz Biomed (MYNZ), Bright Minds Biosciences (DRUG), Evoke Pharma (EVOK), Oragenics (OGEN), Virios Therapeutics (VIRI), Adial Pharmaceuticals (ADIL), Artelo Biosciences (ARTL), Biofrontera (BFRI), and China Pharma (CPHI). These companies are all part of the "pharmaceutical preparations" industry.

Aptevo Therapeutics vs.

Hoth Therapeutics (NASDAQ:HOTH) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Hoth Therapeutics has higher earnings, but lower revenue than Aptevo Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hoth TherapeuticsN/AN/A-$7.84M-$1.94-0.46
Aptevo Therapeutics$3.11M0.41-$17.41MN/AN/A

Aptevo Therapeutics received 133 more outperform votes than Hoth Therapeutics when rated by MarketBeat users. However, 63.11% of users gave Hoth Therapeutics an outperform vote while only 52.52% of users gave Aptevo Therapeutics an outperform vote.

Hoth TherapeuticsOutperform Votes
Underperform Votes
Aptevo TherapeuticsOutperform Votes
Underperform Votes

Hoth Therapeutics has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Aptevo Therapeutics has a beta of 5.2, suggesting that its share price is 420% more volatile than the S&P 500.

In the previous week, Aptevo Therapeutics had 3 more articles in the media than Hoth Therapeutics. MarketBeat recorded 5 mentions for Aptevo Therapeutics and 2 mentions for Hoth Therapeutics. Aptevo Therapeutics' average media sentiment score of 1.44 beat Hoth Therapeutics' score of 0.75 indicating that Hoth Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Hoth Therapeutics Positive
Aptevo Therapeutics Positive

Hoth Therapeutics currently has a consensus target price of $4.00, indicating a potential upside of 349.44%. Given Aptevo Therapeutics' higher possible upside, equities analysts plainly believe Hoth Therapeutics is more favorable than Aptevo Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hoth Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
Aptevo Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)

Aptevo Therapeutics' return on equity of -83.04% beat Hoth Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Hoth TherapeuticsN/A -83.04% -73.34%
Aptevo Therapeutics N/A -221.61%-110.89%

7.1% of Hoth Therapeutics shares are held by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are held by institutional investors. 10.6% of Hoth Therapeutics shares are held by company insiders. Comparatively, 0.3% of Aptevo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.


Hoth Therapeutics beats Aptevo Therapeutics on 7 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APVO vs. The Competition

MetricAptevo TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.35M$7.21B$5.29B$8.67B
Dividend YieldN/A2.75%2.83%4.05%
P/E RatioN/A9.52105.5114.22
Price / Sales0.41286.272,169.6374.66
Price / CashN/A33.2034.7432.47
Price / Book0.015.844.914.46
Net Income-$17.41M$146.83M$110.78M$215.59M
7 Day Performance7.19%10.50%6.14%5.37%
1 Month Performance-59.94%4.69%4.31%3.37%
1 Year Performance-99.54%-0.56%5.54%0.94%

Aptevo Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Hoth Therapeutics
3.273 of 5 stars
3.27 / 5 stars
-69.4%$4.66MN/A-0.452Short Interest ↓
Gap Up
Mainz Biomed
1.2865 of 5 stars
1.29 / 5 stars
-89.7%$4.66M$895,479.00-0.2465Short Interest ↑
Gap Down
High Trading Volume
Bright Minds Biosciences
0 of 5 stars
0.00 / 5 stars
N/A-62.0%$4.66MN/A-1.04N/APositive News
Gap Down
Evoke Pharma
0 of 5 stars
0.00 / 5 stars
N/A-65.9%$4.64M$5.18M-0.304Short Interest ↓
0 of 5 stars
0.00 / 5 stars
N/AN/A$4.55M$40,000.00-0.125Analyst Forecast
Gap Up
Virios Therapeutics
2.8268 of 5 stars
2.83 / 5 stars
-86.9%$4.45MN/A-0.864Short Interest ↓
News Coverage
Adial Pharmaceuticals
0 of 5 stars
0.00 / 5 stars
N/A-86.1%$4.43MN/A0.004Short Interest ↓
Positive News
Gap Down
Artelo Biosciences
2.4603 of 5 stars
2.46 / 5 stars
-37.1%$4.31MN/A-0.426Positive News
2.0661 of 5 stars
2.07 / 5 stars
-89.5%$4.20M$33.25M-0.0683Short Interest ↑
Gap Up
China Pharma
0 of 5 stars
0.00 / 5 stars
N/A-85.0%$4.13M$7.78M0.00231Analyst Forecast

Related Companies and Tools

This page (NASDAQ:APVO) was last updated on 7/13/2024 by Staff

From Our Partners